Medicare must study unproven, expensive Alzheimer’s drug

15 June 2021 - Tax payers and patients cannot afford to pay a high price for a treatment not known to ...

Read more →

Health care funding decisions and real world benefits: reducing bias by matching untreated patients

14 June 2021 - Governments and health insurers often make funding decisions based on health gains from randomised controlled trials.  ...

Read more →

Biogen’s new Alzheimer’s drug could cost Medicare billions of dollars a year, report finds

10 June 2021 - “If 1 million Medicare beneficiaries receive Aduhelm, which may even be on the low end of Biogen’s ...

Read more →

Alzheimer’s drug is bonanza for Biogen, most likely at taxpayer expense

8 June 2021 - The FDA’s decision on Monday to approve a new Alzheimer’s medication over the fierce objections of ...

Read more →

Patients set to pay thousands more as rebates cut in raft of radical Medicare changes

6 June 2021 - A chaotic attempt to modernise the 38 year old Medicare system could see patients hit with higher ...

Read more →

Modernising Medicare coverage pathways for prescription digital therapeutics

13 May 2021 - Outpatient visit restrictions imposed in early 2020 due to COVID-19 increased demand for effective virtual health care ...

Read more →

Allow Medicare to negotiate on behalf of patients to lower drug prices

12 May 2021 - President Biden’s speech announcing his American Families Plan reaffirmed his strong support for legislation to lower ...

Read more →

Medicare beneficiaries can't wait for lower drug prices

7 May 2021 - Medicare beneficiaries have been among the hardest-hit populations by the pandemic for the last 13 months — ...

Read more →

Avelumab not recommended as a maintenance treatment of urothelial cancer after platinum-based chemotherapy

7 May 2021 - NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of locally advanced or ...

Read more →

United Therapeutics announces FDA approval and launch of Tyvaso for the treatment of pulmonary hypertension associated with interstitial lung disease

1 April 2021 - First and only approved therapy in the United States for patients with PH-ILD, a serious, life-threatening ...

Read more →

Update on finalisation of MCIT rule to provide national Medicare coverage for FDA breakthrough devices and diagnostics

15 March 2021 - Renalytix AI provides an update on the establishment of the Medicare Coverage of Innovative Technology (MCIT) ...

Read more →

Medicare’s new device coverage pathway — breakthrough or breakdown?

10 March 2021 - CMS recently finalised a rule that could substantially alter Medicare coverage decisions for certain new medical devices.  ...

Read more →

Sun Pharma announces Drizalma Sprinkle (duloxetine delayed release capsules) is now covered by most Medicare Part D plans

9 March 2021 - Coverage for novel formulation of duloxetine now offered to 91% of lives in top 10 Medicare Part ...

Read more →

With a new president and a new Congress, it's time for Medicare drug price negotiation

20 January 2021 - Since passage of the Medicare Modernization Act in 2003, which prohibited Medicare from negotiating prescription drug prices, ...

Read more →

Changes to Medicare Advantage and Part D will provide better coverage, more access and improved transparency for Medicare beneficiaries

15 January 2021 - Today, the CMS issued a final rule that further advances the agency’s efforts to strengthen and modernise ...

Read more →